Gorakhpur poultry shops shut for 21 days after bird flu cases
Representative image
GORAKHPUR: All poultry shops in Gorakhpur in Uttar Pradesh were asked on Saturday to shut for 21 days following detection of
avian influenza
strains, H5N1 and H9N2, in bird samples from five localities in the city.
Samples were taken at Jhungia Bazar, Aluminium Factory area, Taramandal, Bhagat Chauraha, and Shaheed Ashfaqullah Khan Zoological Park. These were sent to the National Institute of High Security Animal Diseases (NIHSAD) at Bhopal in MP, which confirmed the presence of both strains of the virus.
The chief veterinary officer (CVO) activated district-level Rapid Response Teams and set up a control room at the Sadar Veterinary Hospital to handle the outbreak.
Following the confirmation, additional municipal commissioner, Nirankar Singh, said as per central govt guidelines, culling operations have begun within a 1km radius of the infected zones. All live birds within this zone will be culled and disinfection drives are underway there.
The CVO appealed to the public not to heed to rumours and to cooperate with the administration. A total of 1,328 samples from Gorakhpur and 1,470 samples from the Gorakhpur-Basti division were tested during the surveillance exercise.
The bird flu started from Gorakhpur zoo where four animals - a lion on April 30, leopard Mona on May 8, tigress Shakti on May 7, and a wolf - have so far succumbed to the virus. The zoo has already been shut for containment measures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
3 hours ago
- NDTV
US Researchers Develop New mRNA Vaccine To Fight Covid-19
New Delhi: Amid fresh surge in Covid-19 cases, a team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously evolving viruses such as SARS-CoV-2 and H5N1. While the currently available mRNA vaccines are highly effective at inducing an immune response against Covid, they present challenges like the high amount of mRNA needed to produce them and the constantly evolving nature of the pathogen. "The virus changes, moving the goal post, and updating the vaccine takes some time," said senior author Suresh Kuchipudi, chair of Infectious Diseases and Microbiology at the University of Pittsburgh School of Public Health. To address these challenges, the researchers created a proof-of-concept Covid vaccine using what's known as a "trans-amplifying" mRNA platform. In this approach, the mRNA is separated into two fragments -- the antigen sequence and the replicase sequence -- the latter of which can be produced in advance, saving crucial time in the event a new vaccine must be developed urgently and produced at scale. In addition, the researchers analysed the spike-protein sequences of all known variants of the SARS-CoV-2 for commonalities, rendering what's known as a "consensus spike protein" as the basis for the vaccine's antigen. In mice, the vaccine induced a robust immune response against many strains of SARS-CoV-2. "This has the potential for more lasting immunity that would not require updating, because the vaccine has the potential to provide broad protection," said Kuchipudi. "Additionally, this format requires an mRNA dose 40 times less than conventional vaccines, so this new approach significantly reduces the overall cost of the vaccine." The study, published in the journal npj Vaccines could inform more efficient vaccine development for other constantly evolving RNA viruses with pandemic potential, Kuchipudi said. "We hope to apply the principles of this lower-cost, broad-protection antigen design to pressing challenges like bird flu."
&w=3840&q=100)
First Post
7 hours ago
- First Post
US okays Moderna's 'next generation' Covid-19 vaccine
The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target read more Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS Moderna, a vaccine manufacturer, said late last week that the FDA has authorised its next-generation COVID-19 vaccine. The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target. Moderna's approval was based on a phase 3 randomised controlled trial involving 11,400 participants ages 12 and older. The trial found that a 10-microgram (μg) dose of mNexspike demonstrated a 9.3% higher relative vaccine efficacy (rVE) compared to a 50-μg dose of Spikevax, with a 13.5% higher rVE in adults ages 65 and older. The two vaccinations have identical safety profiles, according to the manufacturer. STORY CONTINUES BELOW THIS AD The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the US has handled COVID-19 vaccines until now, reflecting scepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The news came just days after the Trump administration cancelled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. STORY CONTINUES BELOW THIS AD
The Hindu
8 hours ago
- The Hindu
Health Matters newsletter: Smoke trail of India's tobacco burden
On tobacco use in India fuelling a health and economic crisis, an update on the Covid-19 situation, what's killing Indians, the proposed mixing of various systems of medicine, and more By now, everyone knows that tobacco is deeply unhealthy. You could be living under a rock on a remote mountain top, and you would still know that it is unhealthy. Tobacco, the World Health Organization says, is deadly in any form -- it kills more than 8 million people each year, including an estimated 1.3 million non-smokers who are exposed to second-hand smoke. And yet, over 260 million adults in India are users of tobacco, with the use of smokeless forms being about double that of smoked forms. Tobacco accounts for nearly 1.35 million deaths every year in India, even while the country is the second-largest consumer and producer of tobacco globally. This World No Tobacco Day, marked on May 31, we had two experts writingas about what tobacco use does in our country: Dr. Vid Karmarkar writes on the health and economic costs of tobacco and calls for making tobacco products unaffordable, to discourage their use, while Dr. Kinshuk Gupta proposes the use of Artificial Intelligence (AI) as an adjunct to traditional strategies to help step up tobacco cessation efforts. The message is clear: if you are using tobacco, the best gift you can give yourself is to stop now. Moving on to the issue that's been causing some concern across the country and one we discussed in last week's newsletter, the Covid-19 situation in India, Bindu Shajan Perappadan reports that as of June 2, active cases neared 4,000 with a total of 32 fatalities across the country; experts however have said that there is no reason to panic, but masking up when experiencing symptoms and ensuring high-risk individuals are protected are steps that should be taken. As Dr. Chandrakant Lahariya points out, if we treat every spike as an impending 'wave' and as a 'false alarm', it will strain the health system and workforce, resulting in response fatigue and undermining credibility. Do read The Hindu's edit on this subject too, offering a sober take on what needs to be done in this situation. Meanwhile, the United States Food and Drug Administration has approved drugmaker Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, while however, it cancelled $766 million awarded to Moderna to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu. Go figure! The other issue that is always slow roasting this time of the year, is of course the heat. Scientists say that 4 billion people, about half the world's population, experienced at least one extra month of extreme heat because of human-caused climate change from May 2024 to May 2025, while a study in the Middle East and North Africal found that global warming could be making cancer in women more common and deadly. If you to know why Indian summers are getting hotter, do read this piece by Ajay Singh Nagpure, and if you're wondering why we are talking about the heat during monsoon season, Nitya Mohan Khemka, Indu K. Murthytell you. In other major news, the Indian Medical Association has condemned the proposed introduction of an integrated course combining MBBS and BAMS (Bachelor of Ayurvedic Medicine and Surgery) programmes at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry. Calling the move 'unfortunate', it said this 'unscientific mixing of various systems of medicines will not benefit doctors or patients''. We'll keep track of this for you, going forward. What else has happened this week? A quick round-up for you: Vignesh Radhakrishnanpresents data revealing that the number of Indians dying from cardiovascular diseases and diabetes has surged, while deaths from malaria, diarrhoea, tuberculosis, and perinatal conditions have declined -- as expected with the burden of non-communicable diseases in our country. And speaking of NCDs, do read Dr. Rajan Ravichandran's take on the cheapest way to combat NCDs, while Dr. Priya Chockalingam explains why hypertension and cardiovascular disease are silent killers in our midst. C. Maya, Dr. Chandiran Joseph, Athira Elssa Johnson, Maitri Porechi and I all write and podcast on another factor contributing to NCDs: our diets and nutrition -- the double burden of malnutrition in our country, urban India's rising problem of overnutrition, the importance of micronutrients in our diets and the urgent necessity for nutritional literacy among children to help keep sugar in check. Shonali Muthalay meanwhile, interviews Alexandra Sowa, the author of 'The Ozempic Revolution: A Doctor's Proven Plan for Success to Help You Reverse Obesity, End Yo-Yo Dieting, and Protect Yourself from Disease'. For our tailpiece this week, we have Ramya Kannan's piece on the conjunction of good bugs and perfume: an infectious disease specialist's journey into looking at the skin microbiome to see what perfume is right for you. And here is our list of explainers -- do give them a read to gain insights and have queries answered on a wide range of subjects related to health. Dr. Dhavapalani Alagappan writes on how to be emergency ready in times of health crises Rohini Karandikar and Sandhya P. Koushika explain how circadian rhythms regulate your health Dr. Ennapadam S. Krishnamoorthy and Dr. Rema Raghu tackle the subject of integrating modern medicine with ancient wisdom Dr. Alok Kulkarni writes both on all you need to know about drug addiction and treating it Dr. S. Nagendra Boopathy demystifies calcified coronary artery disease These pieces on menstrual hygiene and pregnancy deal with vital subjects: Drs. Sudha Kallakuri, Deepika Saluja and Josyula K. Lakshmi write on why menstruation is everyone's business; Karan Babbar calls for policy action on menstrual hygiene, Shrabana Chatterjee writes on lack of sanitation facilites keeping menstruating girls off school, Mrutyunjaya Bellad details the urgent need to tackle anaemia before pregnancy, and here is an explanation on preeclampsia, a potentially dangerous complication in pregnancy. Dr. Puneet Kumar decodes a major study that says malaria reinfection creates special immune cells And finally, Rashikkha Ra Iyer proposes that playing chess can galvanise a movement that promotes mental fitness, fosters social connections, and cultivates emotional resilience Do not forget to watch our video, the Health Wrap that offers you a glimpse of everything important in the health sector over the past week, along with an expert's tips and tricks on how to take care of your skin this odd season, in many parts of India, that's all hot and rainy at the same time. Still want something fun and health-related to dig into? Do take this quiz on movies that revolve around health. For many more health stories, head to our health page and subscribe to the health newsletter here.
